Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 15:104:adv40796.
doi: 10.2340/actadv.v104.40796.

Risk Factors Associated with Weight Gain during Treatment with Dupilumab among Patients with Moderate to Severe Atopic Dermatitis

Mahsa Tayefi  1 , Axel Svedbom  2 , Lina Ivert  3 , Maria Lundqvist  4 , Jorge Ruas  5 , Maria Bradley  3 , Emma Johansson  3
Affiliations

Risk Factors Associated with Weight Gain during Treatment with Dupilumab among Patients with Moderate to Severe Atopic Dermatitis

Mahsa Tayefi et al. Acta Derm Venereol. .

Abstract

This cohort study used prospectively collected data from the Swedish national quality registry, SwedAD, to investigate weight gain as a possible side effect of dupilumab treatment for atopic dermatitis. Patients on dupilumab were compared with patients on other systemic medications, e.g., methotrexate, cyclosporine, or Janus kinase inhibitors, and possible risk factors for weight change during treatment with dupilumab were analysed. All patients aged 18 years or above, included in SwedAD between March 2018 and April 2023, who initiated systemic treatment at or after inclusion and had data on weight at baseline and at least 1 follow-up weight measurement were included (n = 157). After 2 years on dupilumab, patients had a mean weight gain of 1.6 kg (p = 0.007, 95% confidence interval [CI] 0.4-2.7). In the multivariable analysis, controlling for age at start, sex, asthma, and body mass index at start, dupilumab was associated with higher weight gain than other systemic treatments (3.3 kg, p = 0.005 [95% CI 1.0-5.6]). Asthma was associated with weight loss; male sex tended to be associated with weight gain.

PubMed Disclaimer

Conflict of interest statement

MT has received speaker honoraria and/or been a consultant for Sanofi-Genzyme, Novartis, and Abbvie. EKJ has received speaker honoraria and/or been a consultant and/or been co-investigator in clinical trials for AbbVie, ACO, Almirall, Amgen, the Swedish Asthma and Allergy Foundation, Galenica, LEO Pharma, Läkartidningen, Novartis, Pfizer, Sanofi-Genzyme, and the Swedish Society for Dermatology and Venereology. She is head of the SwedAD steering committee. MB has received speaker honoraria and/or been a consultant and/or been co-investigator in clinical trials for AbbVie, ACO, Amgen, LEO Pharma, Sanofi Genzyme, Pfizer, Novartis, the Swedish Asthma and Allergy Foundation, Läkartidningen, Swedish Society for Dermatology and Venereology. She is head of the SwedAD steering committee together vid EKJ. LUI has received speaker honoraria and/or been a consultant for ACO, Sanofi-Genzyme, Lilly, LEO, Pfizer, Almirall, and Abbvie. She is a member of the SwedAD steering committee. AS has received lecture fees from Janssen-Cilag and UCB. He has received consultancy fees from Novartis, Eli Lilly, Icon, Abbvie, and BMS. He is a member of the SwedAD steering committee. ML has received lecture fees from Sanofi-Genzyme and Abbvie. She is a member of the SwedAD steering committee. JR has no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Weight change during treatment with dupilumab over 24 months.
See this image and copyright information in PMC

References

    1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet 2020; 396: 345–360. 10.1016/S0140-6736(20)31286-1 - DOI - PubMed
    1. Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. . ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717–2744. 10.1111/jdv.16892 - DOI - PubMed
    1. Ivert LU, Svedbom A, Lundqvist M, Wahlgren CF, Bradley M, Johansson EK. The impact of systemic treatment of atopic dermatitis on depressive symptoms: a prospective clinical cohort study. Acta Derm Venereol 2022; 102: adv00801. 10.2340/actadv.v102.803 - DOI - PMC - PubMed
    1. Ali F, Vyas J, Finlay AY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol 2020; 100: adv00161. 10.2340/00015555-3511 - DOI - PMC - PubMed
    1. Koskeridis F, Evangelou E, Ntzani EE, Kostikas K, Tsabouri S. Treatment with dupilumab in patients with atopic dermatitis: systematic review and meta-analysis. J Cutan Med Surg 2022; 26: 613–621. 10.1177/12034754221130969 - DOI - PubMed

MeSH terms

LinkOut - more resources